Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma
Abstract DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a single therapy. To enhance their activity into the tumor, a DNA vaccine against murine P8...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2018-10-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-018-33933-7 |
| _version_ | 1818345445639847936 |
|---|---|
| author | Alessandra Lopes Kevin Vanvarenberg Špela Kos Sophie Lucas Didier Colau Benoît Van den Eynde Véronique Préat Gaëlle Vandermeulen |
| author_facet | Alessandra Lopes Kevin Vanvarenberg Špela Kos Sophie Lucas Didier Colau Benoît Van den Eynde Véronique Préat Gaëlle Vandermeulen |
| author_sort | Alessandra Lopes |
| collection | DOAJ |
| description | Abstract DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a single therapy. To enhance their activity into the tumor, a DNA vaccine against murine P815 mastocytoma was combined with antibodies directed against the immune checkpoints CTLA4 and PD1. The combination of these two strategies delayed tumor growth and enhanced specific antitumor immune cell infiltration in comparison to the corresponding single therapies. The combination also promoted IFNg, IL12 and granzyme B production in the tumor microenvironment and decreased the formation of liver metastasis in a very early phase of tumor development, enabling 90% survival. These results underline the complementarity of DNA vaccination and immune checkpoint blockers in inducing a potent immune response, by exploiting the generation of antigen-specific T cells by the vaccine and the ability of immune checkpoint blockers to enhance T cell activity and infiltration in the tumor. These findings suggest how and why a rational combination therapy can overcome the limits of DNA vaccination but could also allow responses to immune checkpoint blockers in a larger proportion of subjects. |
| first_indexed | 2024-12-13T17:02:29Z |
| format | Article |
| id | doaj.art-8a185f7e782e4e90bd9cd7722f8cbb6c |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-13T17:02:29Z |
| publishDate | 2018-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-8a185f7e782e4e90bd9cd7722f8cbb6c2022-12-21T23:37:46ZengNature PortfolioScientific Reports2045-23222018-10-018111110.1038/s41598-018-33933-7Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytomaAlessandra Lopes0Kevin Vanvarenberg1Špela Kos2Sophie Lucas3Didier Colau4Benoît Van den Eynde5Véronique Préat6Gaëlle Vandermeulen7Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and BiomaterialsUniversité Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and BiomaterialsInstitute of Oncology Ljubljana, Department of Experimental Oncologyde Duve Institute, Université Catholique de Louvainde Duve Institute, Université Catholique de Louvainde Duve Institute, Université Catholique de LouvainUniversité Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and BiomaterialsUniversité Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and BiomaterialsAbstract DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a single therapy. To enhance their activity into the tumor, a DNA vaccine against murine P815 mastocytoma was combined with antibodies directed against the immune checkpoints CTLA4 and PD1. The combination of these two strategies delayed tumor growth and enhanced specific antitumor immune cell infiltration in comparison to the corresponding single therapies. The combination also promoted IFNg, IL12 and granzyme B production in the tumor microenvironment and decreased the formation of liver metastasis in a very early phase of tumor development, enabling 90% survival. These results underline the complementarity of DNA vaccination and immune checkpoint blockers in inducing a potent immune response, by exploiting the generation of antigen-specific T cells by the vaccine and the ability of immune checkpoint blockers to enhance T cell activity and infiltration in the tumor. These findings suggest how and why a rational combination therapy can overcome the limits of DNA vaccination but could also allow responses to immune checkpoint blockers in a larger proportion of subjects.https://doi.org/10.1038/s41598-018-33933-7P815 MastocytomaImmune Checkpoint Blockers (ICBs)Cancer VaccinationPotent Immune ResponseTumor Growth Delay |
| spellingShingle | Alessandra Lopes Kevin Vanvarenberg Špela Kos Sophie Lucas Didier Colau Benoît Van den Eynde Véronique Préat Gaëlle Vandermeulen Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma Scientific Reports P815 Mastocytoma Immune Checkpoint Blockers (ICBs) Cancer Vaccination Potent Immune Response Tumor Growth Delay |
| title | Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma |
| title_full | Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma |
| title_fullStr | Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma |
| title_full_unstemmed | Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma |
| title_short | Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma |
| title_sort | combination of immune checkpoint blockade with dna cancer vaccine induces potent antitumor immunity against p815 mastocytoma |
| topic | P815 Mastocytoma Immune Checkpoint Blockers (ICBs) Cancer Vaccination Potent Immune Response Tumor Growth Delay |
| url | https://doi.org/10.1038/s41598-018-33933-7 |
| work_keys_str_mv | AT alessandralopes combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma AT kevinvanvarenberg combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma AT spelakos combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma AT sophielucas combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma AT didiercolau combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma AT benoitvandeneynde combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma AT veroniquepreat combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma AT gaellevandermeulen combinationofimmunecheckpointblockadewithdnacancervaccineinducespotentantitumorimmunityagainstp815mastocytoma |